Esperion Therapeutics Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom forecasts quarterly sales below estimates amid rising custom AI chip competition
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Esperion Therapeutics (ESPR) Prices 1.75M Common Offering at $100/Share
March 19, 2015 6:47 AM EDTEsperion Therapeutics (Nasdaq: ESPR) announced the pricing of an underwritten public offering of 1,750,000 shares of its common stock, offered at a price to the public of $100.00 per share. The gross proceeds from this offering to Esperion are expected to be $175 million, before deducting underwriting discounts and commissions... More
Esperion Therapeutics (ESPR) to Offer $150M In Common Stock
March 17, 2015 5:31 PM EDTEsperion Therapeutics (NASDAQ: ESPR) announced that it intends to offer and sell, subject to market and other conditions, $150 million of its common stock in an underwritten public offering. Esperion expects to grant the underwriters a 30-day option to purchase up to $22.5 million of... More
